Author Affiliations: Faculty of Nursing. Pontificia Universidad Javeriana (Ms Achury-Saldaña), Bogota, Colombia; Faculty of Engineering, Pontificia Universidad Javeriana (Dr Gonzalez), Bogota, Colombia; Faculty of Medicine, Pontificia Universidad Javeriana, Bogota (Dr Garcia), Colombia; Pontificia Universidad Javeriana and Heart Failure Clinic Hospital Universitario San Ignacio (Dr Mariño), Bogota, Colombia; and Faculty of Medicine, Pontificia Universidad Javeriana (Dr Bohorquez), Bogota, Colombia.
Comput Inform Nurs. 2024 Jul 1;42(7):522-529. doi: 10.1097/CIN.0000000000001115.
Episodes of decompensation are the main cause of hospital admissions in patients with heart failure. For this reason, the use of mobile apps emerges as an excellent strategy to improve coverage, real-time monitoring, and timeliness of care. ControlVit is an electronic application for early detection of complications studied within the context of a tertiary university hospital. Patients were randomized to the use of ControlVit versus placebo, during a 6-month follow-up. The primary outcome was the difference in numbers of readmissions and deaths for heart failure between both groups. One hundred forty patients were included (intervention = 71, placebo = 69), with an average age of 66 years old; 71% were men. The main etiology of heart failure was ischemic (60%), whereas the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). The primary outcome occurred more frequently in the control group: readmission due to decompensation for heart failure (control group n = 14 vs intervention group n = 3; P = .0081), and death (control group n = 11 vs intervention group n = 3; P = .024). In heart failure patients, ControlVit is a useful and supplementary tool, which reduces hospital admissions due to episodes of decompensation.
失代偿发作是心力衰竭患者住院的主要原因。因此,使用移动应用程序作为改善覆盖范围、实时监测和护理及时性的绝佳策略应运而生。ControlVit 是一种用于早期检测并发症的电子应用程序,在一所三级大学医院进行了研究。患者被随机分配至 ControlVit 组和安慰剂组,随访 6 个月。主要结局是两组心力衰竭再入院和死亡的差异。共纳入 140 例患者(干预组=71 例,安慰剂组=69 例),平均年龄 66 岁;71%为男性。心力衰竭的主要病因是缺血性(60%),主要合并症为高血压(44%)、血脂异常(42%)、甲状腺功能减退症(38%)、慢性肾脏病(38%)和糖尿病(27%)。对照组的主要结局更为常见:心力衰竭失代偿导致再入院(对照组 n=14 例 vs 干预组 n=3 例;P=0.0081)和死亡(对照组 n=11 例 vs 干预组 n=3 例;P=0.024)。对于心力衰竭患者,ControlVit 是一种有用且补充性的工具,可减少因失代偿发作导致的住院。